Ginkgo Bioworks Holdings, Inc. Class A Common Stock DNA 深 沪
等待开盘 04-25 09:30:00 美东时间
0.8458
-0.025
-2.84%
华盛通- 最 高0.895
- 今 开0.89
- 成交量 4551.49万股
- 最 低 0.8168
- 昨 收 0.8705
- 总市值 18.20亿
- 52周最高 2.545
- 市盈率 静 --
- 换手率 2.12%
- 52周最低 0.81
- 委 比 29.41%
- 总股本 21.52亿
- 历史最高 15.864
- 量 比 0.99
- 振 幅 8.98%
- 历史最低 0.81
- 每 手 1
- 风险率 0.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ginkgo Bioworks Reports Acquisition Of AgBiome's Platform Assets
The deal includes over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata, as well as AgBiome's development pipeline. These assets will be
04-11 19:19
Ginkgo Bioworks Awarded Grant for AI-enabled Forecasting of Measles Outbreaks
Ginkgo epidemiological modeling experts and Northeastern University researchers awarded new grant from the Bill & Melinda Gates Foundation BOSTON, April 10, 2024 /PRNewswire/ -- Ginkgo Biowo...
04-10 19:01
Ginkgo Bioworks Acquired Modulus Therapeutics' Cell Therapy Assets; Terms Not Disclosed
Today, Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of Modulus Therapeutics' cell therapy platform assets, including their
04-02 19:10
Imagindairy and Ginkgo Bioworks Collaborate to Develop and Produce Animal-Free Non-Whey Dairy Proteins
Imagindairy and Ginkgo will leverage Ginkgo Protein Expression Services and Imagindairy's process development and scale-up expertise to economically produce non-whey dairy proteins for the f...
03-26 19:02
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
02-29 18:15
Earnings Outlook For Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings (NYSE:DNA) is set to give its latest quarterly earning...
02-28 23:01
Ginkgo Continues To Expect FY23 Total Revenue Of $250M–$260M Versus Consensus Of $258.65M
Preliminary unaudited Cell Engineering revenue is expected to be within the previously disclosed guidance range of $145 – $150 million in 2023. Preliminary unaudited Biosecurity
01-10 20:38
Ginkgo Bioworks Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 3, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason ...
01-03 20:00
Alveolus Bio Enters Into Strategic Collaboration with BiomEdit
CAMBRIDGE, Mass. and BIRMINGHAM, Ala., Dec. 8, 2023 /PRNewswire/ -- Alveolus Bio today announced a strategic scientific collaboration with BiomEdit, an emerging animal health biotechnology c...
2023-12-08 22:00
BTIG Downgrades Ginkgo Bioworks Holdings to Neutral
BTIG analyst Mark Massaro downgrades Ginkgo Bioworks Holdings (NYSE:DNA) from Buy to Neutral.
2023-11-09 22:32
